Company profile
OXcan | Oxford Cancer Analytics
Enabling curative cancer treatment through early detection
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
AP01 | Transaction MzUzMTMwOTE5OGFkaXF6a2N4
Published 08 Jul 2026 18:45
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 May 2023 to 31 Jul 2023
Lung cancer is a leading cause of death worldwide, with non-small cell lung cancer (NSCLC) accounting for up to 85% of all cases and overall a 5-year survival rate of 17.8%. Both early detection and targeted patient-specific therapies of NSCLC are crucial to improve patient survival. As the amount of healthcare data is continuously growing, the diagnosis ...
